@article{e767fb50228540f495cd60a3cf73019d,
title = "ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer",
abstract = "Cato et al. utilize cistrome and transcriptome analyses in castration-resistant prostate cancer (CRPC) to reveal that the androgen receptor (AR) splice variant ARv7 functions as a transcriptional repressor and heterodimerizes with full-length AR at a subset of growth-suppressive genes to support CRPC growth.",
keywords = "AR variant v7 (ARv7), androgen receptor (AR), castration-resistant prostate cancer (CRPC), transcription",
author = "Laura Cato and {de Tribolet-Hardy}, Jonas and Irene Lee and Rottenberg, {Jaice T.} and Ilsa Coleman and Diana Melchers and Ren{\'e} Houtman and Tengfei Xiao and Wei Li and Takuma Uo and Shihua Sun and Kuznik, {Nane C.} and Bettina G{\"o}ppert and Fatma Ozgun and {van Royen}, {Martin E.} and Houtsmuller, {Adriaan B.} and Raga Vadhi and Rao, {Prakash K.} and Lewyn Li and Balk, {Steven P.} and Den, {Robert B.} and Trock, {Bruce J.} and Karnes, {R. Jeffrey} and Jenkins, {Robert B.} and Klein, {Eric A.} and Elai Davicioni and Gruhl, {Friederike J.} and Long, {Henry W.} and Liu, {X. Shirley} and Cato, {Andrew C.B.} and Lack, {Nathan A.} and Nelson, {Peter S.} and Plymate, {Stephen R.} and Groner, {Anna C.} and Myles Brown",
note = "Funding Information: We thank David Labb{\'e}, Teng Fei, Jin Zhao, Didier Trono, Renato Paro, and members of his group for helpful discussions, advice, and technical help. We thank Jutta Stober and Alban Muslija for help with 3D cell culture. We also thank the MBCF (DFCI), particularly Zach Herbert, for help with Illumina sequencing. This work was supported by the Claudia Adams Barr Foundation (L.C.), the Prostate Cancer Foundation (L.C., A.C.B.C., P.S.N., S.R.P., and M.B.) and NIH grant P01CA163227 (L.C., S.P.B., P.S.N., S.R.P., and M.B.). S.R.P. and P.S.N. are funded by the Pacific NW Prostate Cancer SPORE ( P50 CA97186 ), and S.R.P. is additionally funded by DOD W81XWH-13-1-0093 and the Veterans Affairs Research Service . P.S.N. is funded by DOD W81XWH-15-1-0430 and W81XWH-15-1-0562 , A.C.G. was funded by the Swiss National Science Foundation (Ambizione grant PZ00P3_167938 ). X.S.L. is funded by NIH R01HG008927 and DOD PC140817P1 (to MB and XSL). S.P.B. and M.B. were funded by the DF/HCC Prostate SPORE ( P50 CA090381 ). Funding Information: We thank David Labb{\'e} Teng Fei, Jin Zhao, Didier Trono, Renato Paro, and members of his group for helpful discussions, advice, and technical help. We thank Jutta Stober and Alban Muslija for help with 3D cell culture. We also thank the MBCF (DFCI), particularly Zach Herbert, for help with Illumina sequencing. This work was supported by the Claudia Adams Barr Foundation (L.C.), the Prostate Cancer Foundation (L.C., A.C.B.C., P.S.N., S.R.P., and M.B.) and NIH grant P01CA163227 (L.C., S.P.B., P.S.N., S.R.P., and M.B.). S.R.P. and P.S.N. are funded by the Pacific NW Prostate Cancer SPORE (P50 CA97186), and S.R.P. is additionally funded by DOD W81XWH-13-1-0093 and the Veterans Affairs Research Service. P.S.N. is funded by DOD W81XWH-15-1-0430 and W81XWH-15-1-0562, A.C.G. was funded by the Swiss National Science Foundation (Ambizione grant PZ00P3_167938). X.S.L. is funded by NIH R01HG008927 and DOD PC140817P1 (to MB and XSL). S.P.B. and M.B. were funded by the DF/HCC Prostate SPORE (P50 CA090381).M.B. has been a consultant for GTx and Novartis. He receives sponsored research support from Novartis and serves on the Scientific Advisory Board of Kronos Bio. L.C. and A.C.G. are employees of Sanofi and Basilea Pharmaceutica, respectively. The other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = mar,
day = "18",
doi = "10.1016/j.ccell.2019.01.008",
language = "English (US)",
volume = "35",
pages = "401--413.e6",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "3",
}